48 results about "Invertase" patented technology

The invention relates to the technical field of biological catalysis, and discloses an L379A mutant enzyme for preparing rebaudioside I. The enzyme is obtained by the following mutations generated by UGT76G1: leucine of the 379th amino acid sequence is mutated into alanine; the enzyme can be applied to RA in-vitro conversion preparation of RI with higher utilization value, the conversion rate is higher than 50%, and the enzyme activity is remarkably improved by 7 times compared with the original enzyme catalytic conversion enzyme activity. The UGT76G1 mutant disclosed by the invention has the advantages that (1) the blank is filled, and a special enzyme catalyst capable of realizing efficient in-vitro synthesis of rebaudioside I (RI) is provided for the first time; 2) efficiency jump: the catalytic conversion rate is greatly increased from original about 7% to more than 50% (increase gt; and 3) stability and reliability: in the cross-scale reaction of 10mL to 5L, the catalyst has stable catalytic performance, shows excellent industrial application potential, and is suitable for popularization and application.

The invention provides a preparation method and application of a bacterium-enzyme-magnetic nano-cluster composite detoxicating agent, the detoxicating agent takes a Fe3O4-HAP nano-cluster as a magnetic core, the surface of the detoxicating agent is subjected to functional modification, a composite flora composed of bacillus amyloliquefaciens, lactobacillus plantarum and saccharomyces cerevisiae is loaded to form sclerotia, a chitosan shell layer is constructed on the outermost layer, and the bacterium-enzyme-magnetic nano-cluster composite detoxicating agent is prepared. And a compound enzyme consisting of aflatoxin Bdegrading enzyme, zearalenone hydrolase and deoxynivalenol invertase is immobilized. The carrier can efficiently and synchronously degrade aflatoxin, vomitoxin and zearalenone, and can realize rapid separation and recovery through an external magnetic field.

The invention relates to a multi-component ginseng extract containing ginseng polypeptide and a preparation method of the multi-component ginseng extract. The preparation method comprises the following steps: S1, preparing ginseng powder from a ginseng raw material; mixing the ginseng powder with an acidic buffer solution, and carrying out presoaking treatment and homogenate dissolution promoting treatment to obtain ginseng primary pulp; s2, mixing the wall-breaking enzyme system with the ginseng primary pulp, and performing acid wall-breaking treatment to obtain wall-broken primary pulp; mixing an invertase system with the wall-broken primary pulp, and carrying out enzymolysis synchronous glucoside conversion treatment to obtain a crude extract; s3, filtering and separating the crude extracting solution to obtain an extract containing the ginseng polypeptide; the pH values of the ginseng primary pulp, the wall-broken primary pulp and the crude extract are in a range of 4.0-6.0; the wall breaking enzyme system comprises pectinase and cellulase; the invertase system comprises beta-glucosidase and acid protease. The technical problems that in the prior art, a ginseng extract is complex in extraction process, multiple active ingredients are difficult to efficiently extract at the same time, the product quality is low, and the biological activity is poor are solved.

The invention relates to the field of synthetic biology, metabolic engineering and fermentation engineering, and discloses a genetically engineered bacterium and application thereof in production of alpha-ketoglutaric acid.The genetically engineered bacterium comprises the steps that the genetically engineered strain with escherichia coli BW25113 or corynebacterium glutamicum ATCC13032 as a host is constructed; overexpression type isocitrate dehydrogenase genes are integrated through chromosomes, alpha-ketoglutarate dehydrogenase complex genes are knocked out, NADPH invertase is overexpressed through plasmids, and exogenous AKG transporter protein is introduced, so that metabolic flux directional regulation and control and product efflux enhancement are realized; meanwhile, a staged fermentation process is adopted and comprises dynamic gradient adjustment of inorganic phosphorus concentration and two-stage pH control. According to the method, the AKG yield of 78.2 g / L can be obtained under the 5L tank scale, the sugar acid conversion rate reaches 0.68, and the method has the advantages of being high in yield, low in byproduct and controllable in cost. The obtained AKG is suitable for a plurality of fields such as medical intermediates, functional foods and cell culture additives, and has wide industrial application prospects.

The present application relates to the field of agricultural biotechnology, and particularly relates to a molecular marker capable of identifying allelic variations of a soluble acid invertase gene AcoInv-1 in pineapple fruits and application thereof. The molecular marker is amplified by using the following primers: forward primer 5-CTGCGAAATGAACTAGTCAACTC-3 and reverse primer 5-TAGAGAACCGTTCTTGG AATGG-3. The primers can identify allelic variations of the soluble acid invertase gene AcoInv-1 in pineapple fruits, i.e. AcoInv-1a and AcoInv-1b. It is found through research that the two allelic variations are extremely significantly related to the total sugar content of the pineapple fruits. It is proved through verification that the pineapple material of the AcoInv-1a type is related to high sugar content, and the pineapple material of the AcoInv-1a and AcoInv-1b types is related to low sugar content. The application of the molecular marker obtained by the present application in selecting pineapple varieties with high sugar content potential will help to accelerate the breeding selection cycle.

The present application relates to the field of plant genetic breeding, and particularly relates to a kind of evaluation method of asparagus yield. Including the following steps: S1, obtaining young plant period asparagus;S2, measures i variety of young plant period asparagus following parameters: photosynthetic rate A, ribulose-1,5-bisphosphate carboxylase / oxygenase activity B, leaf dry weight per unit area C, acid invertase activity D and root crown ratio E;The measurement sample of the acid invertase activity D is the tender stem of young plant period asparagus at 10-30cm from top;S3, according to the formula, the evaluation value is calculated, and the evaluation value is used to evaluate the yield of asparagus. The evaluation value obtained by using the above measurement index and calculation formula, and the significance level obtained by SPSS software is used to evaluate the yield of asparagus. The yield potential of asparagus can be comprehensively evaluated from the genetic point of view in a short time. Using the evaluation method of the present application, high-yield asparagus varieties can be selected in a short time without tracking for many years.

The invention discloses a preparation method and application of an edible grass leaf source active peptide with ACE (angiotensin converting enzyme) inhibitory activity, and belongs to the technical field of biological active peptides. The preparation method comprises the following steps: firstly, extracting azolla filliculoidas protein from azolla filliculoidas powder by adopting an ultrasonic-assisted alkali-solution and acid-isolation method; dissolving a certain amount of rumex hanus powder in distilled water, adjusting the pH value of the solution, carrying out water bath preheating, and adding neutral protease for enzymolysis; and carrying out ultrafiltration and DEAE Sepharose FF anion gel column separation on the obtained enzymolysis product to obtain the azolla filliculoidas source active peptide with efficient angiotensin converting enzyme inhibitory activity. The preparation method is simple in process, mild in condition and easy to popularize, the obtained active peptide has wide application prospects in development of functional food, health care products and antihypertensive drugs, and effective utilization and value improvement of azolla filliculoidas protein resources are facilitated.

This invention discloses a strain of *Lactobacillus casei* that produces thermostable invertase and its applications. This strain was deposited on August 14, 2023, at the China Center for Type Culture Collection (CCTCC), Wuhan, Hubei Province, China, with accession number CCTCCNO: M20231470. The *Lactobacillus casei* provided by this invention is easy to culture and can produce high levels of thermostable invertase. Its probiotic powder can rapidly degrade sucrose and prevent sucrose intolerance. The metabiotic prepared from this strain can also effectively degrade sucrose and prevent sucrose intolerance.

The invention discloses a multifunctional bioactive peptide from highland barley and application of the multifunctional bioactive peptide. The bioactive peptide has an amino acid sequence as shown in SEQ ID NO: 1. The multifunctional bioactive peptide disclosed by the invention has the activity of inhibiting angiotensin converting enzyme, the activity of inhibiting dipeptidyl peptidase-4, the antioxidant activity and the anti-inflammatory activity, can be used for developing polypeptide medicines or functional foods with a disease treatment effect, and has a good application prospect.

Disclosed are, inter alia, combinations comprising a first antisense (e.g., first double stranded RNAi (dsRNAi)) agent for inhibiting expression of proprotein convertase subtilisin kexin 9 (PCSK9), for example, human PCSK9, and a second antisense agent (e.g., second dsRNAi agent) for inhibiting expression of lipoprotein (a) (Lp(a)); pharmaceutical compositions including the same, and methods of treatment using the same.

This invention provides a sea buckthorn seed protein peptide, its preparation method, and its application, relating to the field of plant protein peptide extraction technology. The preparation method includes: pulverizing defatted sea buckthorn seed residue, performing ultrasonic-assisted extraction, adjusting the pH value to precipitate, and centrifuging to obtain a protein extract; adding a complex protease composed of alkaline protease, flavor protease, and neutral protease in a specific enzyme activity ratio for targeted enzymatic hydrolysis; purifying the hydrolysate sequentially through a 3kDa ultrafiltration membrane and a 1kDa nanofiltration membrane, collecting the permeate; adding an encapsulating agent and spray drying to obtain the final product. The sea buckthorn seed protein peptide prepared by this method has a molecular weight of less than 3kDa (≥85%), a purity of ≥90%, and exhibits excellent DPPH free radical scavenging ability and angiotensin-converting enzyme inhibitory activity. This invention achieves efficient extraction of sea buckthorn seed protein and targeted enrichment of active peptides. The product can be used as a functional food, health product, or pharmaceutical raw material for antioxidation and blood pressure reduction.

The invention belongs to the technical field of development of plant-derived bioactive peptides, and discloses a preparation method and application of a moringa seed antihypertensive polypeptide. Moringa seed polypeptide with the activity of inhibiting angiotensin converting enzyme (ACE) is separated and purified from moringa seed crude protein, nine moringa seed ACE inhibitory peptides with brand-new sequences and the effect of reducing blood pressure are finally obtained through structural identification, activity screening and solid-phase synthesis, sequence modification is conducted on polypeptide PLVRRAIY with the highest activity, and the trypsin enzymolysis resistance of the polypeptide PLVRRAIY is improved. Molecular level and animal experiments show that both the original peptide PLVRRAIY and the modified peptide PPVQQAIY have significant ACE inhibitory activity and antihypertensive effect, the trypsin degradation resistance of the modified peptide in the gastrointestinal tract environment is enhanced, the stability is significantly improved, and a new resource is provided for development of natural antihypertensive polypeptide drugs.

To provide an injection device for subcutaneous administration, for preventing cardiovascular events in a human subject.SOLUTION: The present invention provides an injection device for subcutaneous administration, comprising a fixed dose of 275 mg to 325 mg of an interfering ribonucleic acid (RNAi) agent. The device comprises a double-stranded ribonucleic acid comprising a sense strand and an antisense strand forming a double-stranded region, where the antisense strand comprises the nucleotide sequence of 5'-asCfsaAfAfAfgCfaAfaAfcAfgGfuCfuagsasa-3' (SEQ ID NO: 3), and the sense strand comprises the nucleotide sequence of 5'-csusagacCfuGfudTuugcuuuugu-3' (SEQ ID NO: 4), where a, g, c and u are 2'-O-methyl (2'-OMe) A, G, C, or U; Af, Gf, Cf or Uf are 2'-fluoro A, G, C or U; dT is 2'-deoxythymidine; and s is a phosphorothioate linkage.SELECTED DRAWING: None

Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin / kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.

This invention belongs to the field of food additive content detection and discloses a dual-detection zone test strip for analyzing glucose and sucrose content. The test strip uses Au@Fe, a cluster-polyphenol-metal coordination network nanozyme with high peroxidase activity, as the signal conversion unit. It constructs a multi-enzyme cascade catalytic process by coupling glucose oxidase (GOx) and invertase (IVt). The RGB color channel signals of the test strip are acquired using smartphone image recognition. A concentration signal correlation between glucose and sucrose is established by unifying the dual-detection zone signal benchmark, ultimately achieving highly sensitive and simultaneous accurate detection of both components in a glucose and sucrose coexisting system. With its advantages of portability, visualization, ease of operation, high sensitivity, and accurate results, this test strip can meet the needs of beverage sugar content detection in daily life, providing a valuable detection tool for controlling daily sugar intake to prevent diseases such as diabetes and obesity.

The invention relates to a bifunctional peptide from cyclina sinensis, and belongs to the technical field of polypeptides. The amino acid sequence of the bifunctional peptide disclosed by the invention is His-Tyr-Pro-Gly-Gln-Pro-Tyr, and the amino acid sequence of the bifunctional peptide disclosed by the invention is as shown in the specification. The invention relates to an oligopeptide with alpha-glucosidase inhibitory activity and ACE (angiotensin converting enzyme) inhibitory activity. The invention also discloses a preparation method of the bifunctional peptide. The bifunctional peptide can also be synthesized by adopting a peptide synthesis method or a synthesis and modification method. The bifunctional peptide provided by the invention takes protein from marine cyclina sinensis as a starting point, is cut into active peptide with a specific sequence structure through control of cutting conditions of protease, has remarkable alpha-glucosidase inhibitory activity and angiotensin converting enzyme (ACE) inhibitory activity, has ICvalues of 0.4662 mg / mL and 0.09976 mg / mL respectively, and can be used for preparing the marine cyclina sinensis bifunctional peptide. Therefore, the tea has double physiological functions of reducing blood sugar and blood pressure. The bifunctional peptide provided by the invention can be used for preparing medicines or health-care foods for reducing blood sugar and / or blood pressure, has a clear sequence structure and dual biological activity, and provides a new way for developing multifunctional ocean-derived peptide products.

The present application provides a kind of yeast peptide and its preparation method and application.The yeast peptide provided by the present application contains the following sequence peptide segment: phenylalanine-valine-alanine-leucine-proline, valine-leucine-isoleucine-leucine-lysine and alanine-glycine-leucine-threonine-leucine.The present application provides angiotensin converting enzyme (ACE) inhibitory activity and in vivo blood pressure lowering activity.

Disclosed are, inter alia, double stranded RNAi (dsRNAi) agents inhibiting expression of proprotein convertase subtilisin kexin 9 (PCSK9), for example, human PCSK9, compositions including the same, and methods of treatment using the same.

This invention relates to the field of biopharmaceutical manufacturing technology, and discloses a pine needle extract scalp health repair agent and its preparation method, comprising: using a fixed-bed bioreactor to set an average residence time that simultaneously satisfies the desired reaction and avoids the generation of impurities; and by actively applying transient flow rate disturbances and analyzing the product concentration response, diagnosing the inactivation state of the bioconversion enzyme system online, and compensatingly reducing the flow rate accordingly. This invention avoids the generation of immunogenic impurities; at the same time, by actively diagnosing and compensating for enzyme inactivation, it solves the fundamental problem of yield decline in continuous production, ensuring the absolute stability of the process in long-term operation.

The present application belongs to the field of bioactive peptides. The present application provides an angiotensin converting enzyme inhibitory peptide and a screening method and application thereof, and the amino acid sequence of the inhibitory peptide is GKGLW and / or GDGLKW. The screening method of the inhibitory peptide of the present application uses soybean protein as raw material, adopts targeted alkaline protease and chymotrypsin double enzymolysis technology for preparation and screening, realizes rapid screening of ACE inhibitory peptides, and provides experimental basis for structure-activity relationship. The inhibitory peptide has strong blood pressure lowering activity, high safety and no toxic side effects. The determination of the stability of the digestive tract shows that the inhibitory peptide has good gastrointestinal stability in the gastrointestinal digestion, and can still maintain good activity after entering the blood.

The application provides a scomber ACE inhibitory peptide as well as a preparation method and application thereof, and relates to the technical field of ACE inhibitory peptides.The scomber ACE inhibitory peptide provided by the application comprises an amino acid sequence as shown in SEQ ID NO.1 or SEQ ID NO.2.Through papain enzymolysis, ultrafiltration, gel chromatography, liquid chromatography-tandem mass spectrometry sequence identification and QSAR modeling, the application improves the working efficiency of ACE inhibitory peptide screening, prepares and screens scomber ACE inhibitory peptides with high angiotensin converting enzyme inhibitory effect, and the scomber ACE inhibitory peptides can be used for developing new antihypertensive drugs, and have a wide application prospect.

The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin / kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.

This invention discloses a turtle peptide with angiotensin-converting enzyme (ACE) inhibitory activity, its preparation, and its application, belonging to the field of biotechnology. Using turtle as raw material, this invention obtains peptide components with a molecular weight less than 5 kDa through enzymatic hydrolysis and ultrafiltration. Sequencing reveals three peptide sequences with ACE inhibitory activity: AAGPAGGNLN, EAGAQGPPGA, and GARGDK. In vitro activity experiments verified the ACE inhibitory function of the three turtle peptides. The turtle peptide combination prepared by this invention exhibits significant ACE inhibitory activity and can be used to develop functional foods or antihypertensive drugs. Furthermore, the preparation method is environmentally friendly, efficient, and suitable for industrial production.

The present application relates to the technical field of biological catalysis, and discloses an L379A mutant enzyme for preparing rebaudioside I and application thereof, wherein the enzyme is obtained by making the following mutation to UGT76G1: the leucine in the 379th amino acid sequence is mutated into alanine; the enzyme can be applied to the preparation of RI with higher utilization value through in-vitro conversion of RA, and the conversion rate is higher than 50%, and the catalytic conversion enzyme activity is significantly improved by 7 times compared with the original enzyme. The UGT76G1 mutant discovered in the present application has the following advantages: 1) filling the blank: the special enzyme catalyst for realizing the efficient in-vitro synthesis of rebaudioside I (RI) is provided for the first time; 2) efficiency leap: the catalytic conversion rate is greatly improved from the original about 7% to more than 50% (more than 7 times); 3) stable and reliable: the catalytic performance is stable in the cross-scale reaction of 10 mL to 5 L, and excellent industrial application potential is exhibited; and the present application is suitable for popularization and application.

This invention relates to the field of agricultural biotechnology, specifically to a molecular marker and its application for identifying allelic variations of the soluble acid invertase gene AcoInv-2 in pineapple fruit. This molecular marker is amplified using the following primers: forward primer: 5-AGCGAGCACGCCGACATCC-3, reverse primer: 5-CGTCTATATTTGAGGACGACTAGT-3. These primers can identify the allelic variation types of the soluble acid invertase gene AcoInv-2 in pineapple fruit: AcoInv-2a and AcoInv-2b. Studies have shown that both allelic variation types are significantly correlated with the total sugar content of pineapple fruit. Verification has demonstrated that pineapple materials with the AcoInv-2a type are associated with high sugar content, while pineapple materials with both AcoInv-2a and AcoInv-2b types are associated with low sugar content. The application of the molecular marker obtained in this invention in selecting pineapple varieties with high sugar content potential will help accelerate the breeding selection cycle.

Disclosed are, inter alia, combinations comprising a first antisense (e.g., first double stranded RNAi (dsRNAi)) agent for inhibiting expression of proprotein convertase subtilisin kexin 9 (PCSK9), for example, human PCSK9, and a second antisense agent (e.g., second dsRNAi agent) for inhibiting expression of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR); pharmaceutical compositions including the same, and methods of treatment using the same.

Disclosed are, inter alia, combinations comprising a first antisense (e.g., first double stranded RNAi (dsRNAi)) agent for inhibiting expression of proprotein convertase subtilisin kexin 9 (PCSK9), for example, human PCSK9, and a second antisense agent (e.g., second dsRNAi agent) for inhibiting expression of angiotensinogen (AGT); pharmaceutical compositions including the same, and methods of treatment using the same.

Aspects of the technology relate to a composition comprising: (i) a first RNAi agent that targets Proprotein convertase subtilisin / kexin type 9 (PCSK9) and a second RNAi agent that targets angiotensinogen (AGT); (ii) a first RNAi agent that targets PCSK9 and a third RNAi agent that targets Apolipoprotein A (LPA); (iii) a second RNAi agent that targets AGT and a third RNAI agent that targets LPA, or (iv) a first RNAi agent that targets PCSK9, a second RNAi agent that targets AGT, and the third RNAi agent that targets LPA.

The invention discloses a method for producing an active rhBMP9 bone repair material based on a double-transgene bombyx mori silk gland biosynthesis system as well as a product and application of the active rhBMP9 bone repair material, and realizes cooperative expression of complex precursor protein Pro-mhBMP9 and precursor protein invertase hFurin in bombyx mori posterior silk glands. An hBMP9 / hFurin double-gene biosynthesis system capable of completing precursor protein shearing, maturation and functionalized silk material synthesis in vivo is established, the rhBMP9 / CaP / Sericin composite scaffold is further constructed by extracting silk protein of double-gene transformation bombyx mori, and the rhBMP9 / CaP / Sericin composite scaffold shows excellent bone repair and angiogenesis capacities in both the cell level and the animal level, and can be used for preparing a bone repair material. And a solid experimental and theoretical basis is provided for a functional protein-material-tissue regeneration integrated strategy based on a silk gland biosynthesis system.